Cross Shawn 4
4 · Applied Molecular Transport Inc. · Filed Dec 28, 2023
Insider Transaction Report
Form 4
Cross Shawn
Chief Financial Officer
Transactions
- Disposition to Issuer
Common Stock
2023-12-27−545,499→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−668,000→ 0 totalExercise: $0.39Exp: 2033-03-24→ Common Stock (668,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−94,500→ 0 totalExercise: $8.29Exp: 2032-02-15→ Common Stock (94,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−63,000→ 0 totalExercise: $56.61Exp: 2031-03-01→ Common Stock (63,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−84,000→ 0 totalExercise: $3.99Exp: 2032-05-16→ Common Stock (84,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−300,000→ 0 totalExercise: $4.61Exp: 2030-03-30→ Common Stock (300,000 underlying)
Footnotes (4)
- [F1]Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").
- [F2]Upon consummation of the Merger, the Reporting Person received Transaction Consideration of 72,606 shares of Cyclo common stock.
- [F3]Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
- [F4]Pursuant to the Merger Agreement, this option was exchanged for an option covering 88,910 shares of Cyclo Common Stock.